Form 4: PepGen Inc. CEO Acquires Shares and Stock Options

James G. McArthur, President and CEO of PepGen Inc., reports acquisition of shares and stock options.

Summary

• On March 3, 2025, James G. McArthur, the President and CEO of PepGen Inc., acquired 60,719 shares of common stock and disposed of 62,413 shares.
• McArthur also acquired 271,875 stock options with an exercise price of $2.81, exercisable starting March 3, 2026, and expiring on March 2, 2035.
• The 60,719 shares acquired consist of restricted stock units (RSUs) that vest in equal annual installments over four years, starting March 3, 2026, contingent upon continued service with the company.
• The stock options vest 25% on the one-year anniversary of the grant date and the remainder in 36 equal monthly installments, also subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by the CEO suggests confidence, but the disposal of shares tempers the positive outlook.

Positives

• The acquisition of RSUs and stock options by the CEO signals confidence in the company's future performance.
• The vesting schedules for both RSUs and stock options incentivize long-term commitment from the CEO.

Negatives

• The disposal of 62,413 shares of common stock by the CEO could be interpreted negatively by investors.

Risks

• The value of the stock options is dependent on the future performance of PepGen Inc.'s stock price.
• The vesting of RSUs and stock options is contingent upon the CEO's continued employment with the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued employment and company performance.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates the CEO's ongoing investment in PepGen.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices for executives in the biotechnology industry, aligning their interests with those of shareholders.
• The vesting schedules described are fairly standard, encouraging long-term commitment.
• Comparable companies like Sarepta Therapeutics or BioMarin Pharmaceutical also utilize similar equity-based compensation strategies.

Stakeholder Impact

• The transactions may influence investor sentiment regarding PepGen Inc.'s prospects.
• The equity-based compensation aligns the CEO's interests with those of shareholders.

Key Dates